Cystatins are small proteins, typically composed of 100-120 amino acids, which together with similar proteins devoid of inhibitory properties, belong to a cystatin 'superfamily'. Cystatins can do more than just inhibit proteases: two important aspects described here are aggregation properties linked to misfolding diseases and the unique ability of monellin, a plant cystatin, to elicit sweet taste. The explanation of the puzzling phenomenon of 'sweet proteins' required an indepth structural study of monellin, also regarding the causes of the high thermal stability of its single chain structure. The detailed mechanisms by which cystatins aggregate could be relevant in the study of misfolding diseases involving cystatins. They are reviewed here with emphasis on 3D domain swapping, typical of aggregating cystatins. While studying monellin, we noticed that it aggregates in a conventional way, probably through the cross-b spine mechanism. However, several cystatins derived from oryzacystatin_I to emulate the taste behavior of monellin aggregate via different mechanisms.
Introduction
Cystatins belong to a family of small proteins whose main characteristic is to be cysteine protease inhibitors (1) . They are typically composed of 100-120 amino acids, are acidic and contain four conserved cysteine residues that form two disulfide bonds (2) . During the 1980s several sequences with high homology to cystatins were discovered. Although not all of them are inhibitors and not all contain disulfide bridges, they were collectively classified, together with cystatins, in a cystatin 'superfamily' (3) .
Cystatins can do more than just inhibit proteases. Two important aspects that will particularly be dealt with in this short update on cystatins are aggregation studies with regard to misfolding diseases and the unique ability of monellin, a plant cystatin, to elicit sweet taste in primates. The explanation of the puzzling phenomenon of 'sweet proteins' required an in-depth structural study of this very interesting cystatin, particularly regarding the features of its surface, but also the causes of the high thermal stability of single chain constructs of monellin. While studying monellin, we noticed that it aggregates in a conventional way, probably through the cross-b spine mechanism. However, several cystatins derived from oryzacystatin_I to emulate the taste behavior of monellin aggregate via different mechanisms. The detailed mechanisms by which cystatins aggregate could be relevant in the study of misfolding diseases involving cystatins. The three main mechanisms proposed for the formation of pathological aggregates are cross-b spine, end-to-end stacking and 3D swapping (4) . In the case of cystatins, the 3D domain swapping mechanism seems particularly relevant, being associated with cystatin C amyloid angiopathy (5), but cystatin aggregation has also been studied in vitro as a typical example of an amyloid-forming protein (6) . In this review, we revisit these unconventional aspects of cystatins.
Sweet cystatins
One of the first two intensely sweet proteins unambiguously identified was monellin, the sweet principle of Dioscoreophyllum cumminsii, a plant taxonomically related to the sweet potato (7) . Owing to the exceptional intensity of the sweet taste, these authors called the plant 'serendipity berries' (8) . Morris and Cagan (9) established that the sweet principle is a protein and named it monellin, after the institute where they worked, the Monell Chemical Senses Center. They measured for monellin, a relative sweetness, and compared it to that of sucrose, yielding ratios of 3000:1 on a weight basis and 90 000:1 on a molar basis. Bohak and Li (10) showed that monellin consists of two subunits of 42 and 50 amino acid residues, called A and B, respectively, that are not covalently joined but only held together by secondary forces. They also established that the sweetness of monellin is exhibited only by the undissociated, whole molecule, whereas the individual subunits are not sweet.
Monellin has no significant sequence similarity with other sweet proteins. In addition, it was not immediately obvious whether it belonged to a known protein family. By comparing the solid state structure of monellin with those of chicken cystatin (11) and of human stefin B (12), Murzin (13) showed that, despite a low sequence similarity with these two cystatins, monellin does belong to the cystatin superfamily. Monellin, similar to all cystatins, forms a wedge-shaped structure consisting of a five-strand b-sheet partially 'wrapped' around an a-helix. The NMR structure of MNEI, a single chain monellin (vide infra) shown in Figure 1A , has all the structural features typical of cystatins (14) .
However, monellin lacks key residues in regions corresponding to the cystatin active site and therefore does not function as a cysteine protease inhibitor. When heated above 508C, monellin dissociates into two chains and loses sweetness, but single chain constructs, in which the two chains are covalently linked, have considerable thermal stability while retaining the sweetening power of wt monellin (16, 17) . In the single chain monellin designed by Kim and colleagues (16) , the C-terminal residue of the B chain (B50E) is directly joined to the N-terminal residue of the A chain (A1R). The covalent link makes single chain monellin very stable against temperature or pH changes; a very similar behavior was demonstrated by MNEI, a single chain monellin obtained by linking B and A chains via a Gly-Phe dipeptide (17) . The structures of wt monellin and of the two mentioned single chain forms have been characterized by several X-ray and NMR studies (14, (18) (19) (20) . All structures are characterized by an a-helix surrounded by the concave side of a five-strand antiparallel b-sheet.
Monellin, similar to the few other sweet proteins, has a molecular volume two orders of magnitude larger than most small molecular weight sweeteners. At first, the only conceivable way to explain the interaction with the same receptor active site seemed the possible existence, on the surface of monellin, of some kind of 'sweet finger', i.e., a protruding structural element hosting moieties (glucophores) similar to those that characterize small sweeteners. The sequence TyrA13-AspA16 of native monellin was suggested as a potential sweet finger (21) , and a preliminary structural study on the solution conformation of MNEI showed that the relative spatial arrangement in solution of the side chains of Tyr65 and Asp68 (corresponding to TyrA13-AspA16 of monellin) is consistent with the corresponding arrangement of the side chains of Phe and Asp in aspartame (17) .
The sweet finger hypothesis was abandoned because cyclic peptides corresponding to the potential sweet fingers of monellin, brazzein and thaumatin, while assuming conformations consistent with the conformation of the same sequences in the parent proteins, are tasteless (22) . The only convincing explanation of the sweet taste of these proteins was furnished by the so-called 'wedge model' (23, 24) . Mammals have only one sweet taste receptor, the T1R2-T1R3 heterodimer. Both protomers (T1R2 and T1R3) belong to class C G protein coupled receptors (GPCRs). In addition to the seven transmembrane helices (7TM) domain, common to all GPCRs, these receptors have a large extracellular domain, called Venus flytrap (VFT) domain, which contains the active site for typical ligands and a connecting Cys rich domain (25) .
The T1R2-T1R3 receptor can interact with molecules of widely different chemical nature: sugars, amino acids, peptides, proteins and many synthetic sweeteners (26) . The majority of small molecular weight compounds are recognized by active sites hosted in the VFT domains. Model building and in silico docking clarified the different role of VFTs belonging to closed or open chains (24) . A third site, located in the 7TM domain, is specific for cyclamate and also for lactisole, a sweet taste inhibitor (27) , but monellin, and the other sweet proteins, are too large to interact with any of these sites. When the T1R2-T1R3 receptor is activated by a small sweetener, the equilibrium between a resting, open-open, form (Roo) of both T1R2 and T1R3 is shifted towards an active, open-closed, form (Aoc). We have shown by in silico studies that this equilibrium can also be shifted when Aoc is stabilized by external binding of a macromolecule on a secondary binding site, located on the receptor surface, composed mainly of a large cavity of the T1R3 protomer in the Aoc form (23, 24) . Figure 1B shows the shift of the equilibrium between Roo and Aoc induced by MNEI. The large cavity on the T1R3 protomer is characterized by a negative electrostatic potential. It is significant that the electrostatic potentials of the T1R3 protomer cavity and the wedge shaped surface of MNEI have largely complementary charges. Figure 1C shows the electrostatic surface of MNEI that can interact with an external site of the sweet receptor. The complex of MNEI with the sweet receptor, as proposed by in silico docking, is shown in Figure 1D . This mechanism, termed the 'wedge model' had been validated by several indirect studies (25) but it was also recently supported by a direct attempt to change a tasteless cystatin into a sweet protein (28) .
Changing a tasteless cystatin into a sweet protein
Is it possible to change a tasteless cystatin into a sweet cystatin? To answer this question, we have recently designed several mutants of oryzacystatin_I (henceforth called ORYZ), a tasteless cystatin. Like monellin, ORYZ belongs to the cystatin superfamily and shares with it a similar fold and plant origin. For this protein alchemy to be meaningful, it is necessary to make ORYZ more similar to MNEI, with only a limited number of mutations (28) .
To design mutants of ORYZ we chose to compare its sequence with that of a single chain monellin (MNEI). We aligned the sequences mainly on the basis of structural elements, because no relationship is expected, a priori, between the sequences whereas the similarity of their fold is selfevident. The structural alignment was performed using the program DALI (29) on the pdb files 1eqk (NMR structure of ORYZ) and 1fa3 (NMR structure of MNEI). The N-terminal peptide of ORYZ, which is completely disordered in the NMR solution structure (30) , is essential for cysteine protease inhibitors (31) but not for the sweet taste of MNEI, which lacks inhibitory activity. In addition, the NMR solution structure (30) also shows that the C-terminal part of the construct is completely disordered. Accordingly, most of the constructs designed to make ORYZ sweet lacked either the nine N-terminal residues or the four C-terminal residues or both.
Initially, most mutations were designed to make the surface of interaction more positive, because the interaction of MNEI with the sweet receptor is dominated by an electrostatic interaction between the negatively charged surface of T1R2-T1R3 and the positively charged wedge-like surface of monellin.
The importance of this electrostatic interaction is simply underlined by the comparison of the isoelectric points of MNEI (9.03) and of ORYZ (4.78). Figure 2 shows a comparison of the surfaces of MNEI (Figure 2A ) and of ORYZ ( Figure 2C ) with the eight main point mutations aimed at changing the electrostatic potential (N17D, E18Q, D25N, E45N, E65Y, E76R, K78D and E92R). The constructs containing these mutations were expressed independently and finally accumulating the changes. In spite of the reasonable similarity between the surfaces of the two proteins, none of the mutated constructs was significantly sweet.
We attributed the main cause of this failed attempt to steric hindrance, rather than to details of the electrostatic surface. The main difference between the putative interacting surfaces of MNEI and ORYZ resides is the length of the L 34 that had previously been suggested as a possible 'sweet finger' (22 . It is possible to see that, in addition to specific differences, the loop of ORYZ ( Figure 2D ) is considerably longer than that of MNEI ( Figure 2B ). We designed an ORYZ construct that, while retaining previous point mutations, included an L 34 loop closer to that of MNEI: Y 61 FTIYASDKLYEA
77
. This protein, although not as sweet as monellin, proved sweet in the micromolar range (28) . This result is both a good starting point to design very sweet cystatins and, at the same time, a good validation of the 'wedge model' of interaction of proteins with the sweet receptor (24) .
Aggregating cystatins
A large number of diseases are characterized by the presence of aggregates of misfolded proteins. The emphasis on misfolding and its possible consequences on aggregation phenomena are so great that these diseases are sometimes termed 'conformational diseases' (32). It is not yet clear whether the toxic species are the large aggregates of fibrils or oligomeric species (33) (34) (35) (36) . In both cases, for a better understanding of the pathogenic behavior, it is of paramount importance to characterize the whole aggregation pathway. There are, in principle, many diverse ways for proteins and peptides to aggregate, but it has been suggested that the three most likely mechanisms for the formation of pathological aggregates are the cross-b spine, end-to-end stacking and 3D swapping (4). The cross-b spine mechanism has been observed in the formation of classical amyloid fibrils, associated with the most well-known conformational diseases, e.g., Alzheimer's, Parkinson's and Huntington's diseases. The 3D domain swapping mechanism seems particularly relevant in the case of cystatins (4), but it can also play a role in other diseases, such as the Unverricht-Lundborg disease (37) and the prion diseases (38) .
Aggregation of human cystatin C plays an important role in the development of cerebral hemorrhage in people with hereditary cystatin C amyloid angiopathy, an autosomal dominant disease (5) . Mutations in the cystatin C gene are responsible for this hereditary cerebral amyloid angiopathy: the L68Q mutant is deposited as amyloid aggregates, causing brain hemorrhage in early adulthood (39) . The observation that cystatin C binds amyloid b, reducing aggregation and deposition, has made it a potential target in Alzheimer's disease (40, 41) . Cystatin C has also been implicated in multiple sclerosis and other demyelinating diseases but its role remains controversial (42) .
Cystatin C is one of the few amyloidogenic proteins for which a detailed mechanism of amyloid fiber formation has been proposed. Cystatin C is normally a monomer, both in vivo and in vitro, and it can be turned into a dimer only at elevated temperature, low pH or using chemical denaturation. On the contrary, L68Q cystatin C can dimerize at the temperature of the human body and is indeed found in dimeric form in vivo (6, 43) . The nature of the aggregation has been elucidated by well-designed crystal structure determinations (44) . The solid state structures of wt (45) and Ntruncated cystatin C (46) show dimers and oligomers originating from 3D domain swapping (47) .
3D domain swapping is an oligomerization in which the formation of dimers and, subsequently, oligomers is prompted by the exchange of protein domains. The swapped domain can be a piece of secondary structure or a whole globular domain, and it is linked to the main body of the protein by a hinge. As shown in Figure 3 , dimerization can occur when a pair of monomers, containing two domains linked by a hinge, exchanges the domains by a rotation about the hinge loop.
Other misfolding diseases related to members of the cystatin family are linked to stefins.
The main pathology caused by cystatin B gene mutations is the Unverricht-Lundborg disease (48) . Although cystatins and stefins diverted early in the evolution, a database search shows that stefins have undergone small changes in function over the evolution, keeping their role of protease inhibitors (49) . Figure 4 shows dimerization through domain swapping as it occurs for cystatin C and stefin B. Stefins and cystatins share high sequence similarity and nearly the same fold. The fold of stefins, similar to those of monellin or cystatin C, consists of a five stranded antiparallel b-sheet wrapped around an a-helix (11) . Another characteristic feature, common to stefins and cystatins (and possibly some other amyloid proteins), is domain swapping, but there are subtle, interesting differences. The main differences were at the level of tetramers. Jenko Kokalj et al. (50) and Kenig et al. (51) screened several stefin mutants to find stable constructs of stefin B, which could form a tetramer. The crystal structure of the tetrameric P79S mutant of Y31-stefin B revealed that on top of the domain swapping mechanism interlinking two pairs of chains, there is an additional crosslinking mechanism, termed handshaking (50), which involves the second hairpin loop. Figure 4C shows the dimer of stefin B in comparison with that of cystatin C.
Aggregation of oryzacystatin constructs
The cases of cystatin C and stefins might give the impression that domain swapping is the only mechanism of aggregation for all cystatins, but the actual situation is more complex, as indicated by the behavior of native monellin, also a member of the cystatin superfamily (3). Konno et al. (52) have shown that monellin undergoes typical amyloid aggregation, accompanied by formation of cross-b fibers. As mentioned above, native monellin is composed of two non-covalently bonded chains, A and B, where chain B occupies the N-terminal position of the cystatin fold. Konno (53) has shown that isolated chain B can form amyloid fibers, whereas chain A does not give significant amounts of aggregates. Surprisingly, according to this author, a single chain monellin in which the C-terminal residue of chain B is covalently linked to the N-terminal residue of chain A (16) does not form amyloid fibers.
We have recently studied in depth the stability and aggregation behavior of monellin in comparison with other cystatins, taking advantage of the many mutants of ORYZ generated by the attempt of converting oryzacystatin into a sweet protein (28, 54) . Aggregation conditions for monellin are particularly harsh. Konno et al. (52) heated monellin for 3 h at pH 2.5 and at 858C to observe formation of typical amyloid fibers. Presumably, these conditions depend on the very high thermal stability of single chain monellins. The melting temperature (T m ) of monellin at pH 7.0 is 73.18C, with a free energy of melting of 6.2 kcal/mol (54) . ORYZ, and the constructs derived from it, are also very stable: the parent protein has a T m of 93.58C at pH 7.0, with a free energy of melting of 4.4 kcal/mol.
All proteins were exposed to very high temperature to induce aggregation but in spite of their comparable thermal stability and the similarity of their three-dimensional architecture, MNEI and ORYZ aggregate in a different way. Using the ThT fluorescence assay, size exclusion chromatography and transmission electron microscopy, Esposito et al. (54) showed that MNEI gives rise to amyloid aggregation upon incubation at high temperature, whereas ORYZ yields amorphous aggregates. Figure 5 shows relevant experiments for the two proteins and sketches of the different types of aggregates. The different nature of the aggregates was evidenced by size exclusion chromatography. Unheated samples of MNEI eluted with an elution volume consistent with a monomeric protein but, after 6 h of incubation at high temperature, the peak area of the monomer decreased by 80%, indicating that the MNEI monomer disappears during the incubation and that species with higher molecular weight (not visible as a precipitate and not eluted from the column) are being formed. This behavior is consistent with the formation of amyloid fibers that become trapped in the gel.
In the case of ORYZ all protein visibly precipitates during the incubation at high temperature and no protein was detected in gel filtration analyses. However, after 3 h of incubation at 508C gel filtration of ORYZ (black dotted line in Figure  5C ) revealed the presence of a trimeric species, in addition to the monomeric protein. It is possible that the early formation of a stable oligomeric species prevents amyloid-like aggregation for ORYZ, eventually leading to an amorphous precipitate.
The mutants designed to create a sweet tasting ORYZ were also tested for stability and aggregation. Most mutants were based on the construct missing the first nine N-terminal residues (DN-ORYZ). All mutants are correctly folded as determined from their circular dichroism and NMR spectra.
The nature of the aggregates formed after heating these constructs was checked, as for the parent proteins, using the ThT assay. The time dependence of ThT fluorescence emission intensity at 482 nm upon incubation at 868C showed that nearly all constructs behave as the parent protein. The only construct that shows a tendency to form amyloid fibers is DNC-ORYZ. These findings have suggested that, in spite of the fact that in the solution structure the two terminal regions appear completely disordered, they have some structural role. It is possible that they can effectively shield regions of the protein surface, otherwise prone to association. The fact that both regions appear completely disordered in the NMR structure can only reflect a conformational equilibrium in solution.
The different mechanism of aggregation of MNEI and ORYZ could be attributed to small but significant differences in their sequences. 
Outlook
Both features of cystatins described here, i.e., sweetness and aggregation properties, although unusual, can lead to interesting developments, if studied in depth.
The difference in aggregation behavior of monellin and oryzacystatin tells us that the reality of protein misfolding and ensuing aggregation is probably more complicated than it appears from recent literature. Our observations are in the wake of the pioneering work of Eisenberg and collaborators. The main lesson to be drawn from our data is that there is more to aggregation than just destabilization and starting structure. Details of protein sequence can be, at times, more important than other parameters.
Altogether, oryzacystatin_I appears a very promising model system for future aggregation studies. Both mechanisms observed in the two cystatin model systems investigated in the present study can lead to toxicity in diseases characterized by aggregates of misfolded proteins.
Looking at the sweet side of cystatins, the indication that it is possible to design new sweet proteins can open new possibilities in the design of innocuous sweeteners, but it is not the only interesting aspect of this unusual cystatin. It must be born in mind that, out of three well-characterized sweet proteins, i.e., monellin, thaumatin and brazzein, two are typical proteinase inhibitors. This observation seems to suggest the possibility that protein inhibitors can be very versatile, simply because they are designed to interact with other proteins. Monellin is a cystatin that has lost the ability to inhibit proteases, but not that of binding tightly to other proteins (inhibitors or otherwise). It would be interesting to investigate systematically whether proteins belonging to families of protein inhibitors do possess other functionalities. It is worth mentioning, in this context, that there is at least one other family of protease inhibitors, that is serpins, with characteristics similar to those of cystatins. Serpins are a group of proteins with similar structures whose acronym comes from the words serine protease inhibitors (55) . Certain serpins do not inhibit proteolytic enzymes, but perform diverse functions as diverse as storage (ovalbumin, in egg white), hormone carriage proteins (thyroxine-binding globulin, cortisol-binding globulin) and tumor suppressor genes (maspin). Serpins, in their mechanism, undergo domain swapping that can eventually lead to polymerization, causing cell death and organ failure, such as liver cirrhosis.
